Clinical Trial Update: An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody [Phase 2]

View source ↗

Summary

Phase 2 exploratory trial investigating SHR6390 and SHR1020 for esophageal squamous cell carcinoma after progression on PD-1 antibody therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• SHR1020
• SHR6390 (SHR6390)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Esophageal Squamous Cell Carcinoma, Progression to PD-1 Antibody | Phase 2 | Status: UNKNOWN